ClinicalTrials.gg
CompletedNCT00931710EXALTUpdated Mar 7, 2011Results posted

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

A Phase 4 interventional study of valsartan, amlodipine, HCTZ and Losartan, HCTZ followed by valsartan, amlodipine, HCTZ in Stage 2 Systolic Hypertension, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-07.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Isolated Systolic Hypertension with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Isolated Systolic Hypertension · United States.

Enrollment
3rd of 12
488 · median 145
Started
2009
the only one that year
Phase 4
2 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
Novartis

Among the 13 studies in Isolated Systolic Hypertension with a site in United States, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 4, and was the 5th registered.

Isolated Systolic Hypertension

35 studies on the registry are indexed under Isolated Systolic Hypertension; 8 are open to participants now.

Browse Isolated Systolic Hypertension studies →

Open to participants now

3 of the 13 studies in Isolated Systolic Hypertension with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Isolated Systolic Hypertension studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Isolated Systolic Hypertension with a site in United States, or all of them as a file.
02

Study summary

This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg).

03

Conditions studied

  • Stage 2 Systolic Hypertension

Keywords

  • Hypertension
  • combination therapy
  • valsartan
  • cardiovascular diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatient of 18 years of age or greater
  • Stage 2 systolic hypertension defined as office Mean Sitting Systolic blood pressure (MSSBP) greater than or equal to 160 and \< 200 mmHg at randomization
  • Patients who were able to participate in the study, and who gave written before any study assessment was performed.

Exclusion criteria

Exclusion Criteria:

  • Office systolic blood pressure >200 and/or mean sitting diastolic blood pressure (MSDBP) greater than or equal to 110 mmHg at Visit 1.
  • Use of four (4) or more antihypertensive medications within 30 days of Visit 1.
  • hypertension, defined as blood pressure >140/90 mmHg while taking three (3) drugs at the maximum dose of each drug, one of which must be a diuretic. (Therapy with a fixed-dose combination of two active medications represents two drugs).
  • Inability to safely discontinue all antihypertensive medications for 1-2 weeks prior to randomization.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Valsartan/amlodipine/HCTZ

    Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.

    Drug: valsartan, amlodipine, HCTZ

  • Active comparator
    Losartan/HCTZ

    Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.

    Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ

Interventions

  • Drugvalsartan, amlodipine, HCTZ

    Drug pages: Valsartan · Amlodipine · Hydrochlorothiazide

    combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study

  • DrugLosartan, HCTZ followed by valsartan, amlodipine, HCTZ

    Drug pages: Losartan · Hydrochlorothiazide · Valsartan · Amlodipine

    losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure After 6 Weeks

    To compare the change from baseline in mean sitting systolic blood pressure (MSSBP) after 6 weeks of valsartan/amlodipine-based regimen with a losartan-based regimen in patients with Stage 2 systolic hypertension.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks

    To compare the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

    Time frame: Baseline to Week 6

  2. Cumulative Percentage of Patients Achieving Blood Pressure Control

    To compare the percentage of patients achieving blood pressure control (defined as patients achieving MSSBP \< 140 mmHg and MSDBP \< 90 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

    Time frame: 3 and 6 weeks

  3. Cumulative Percentage of Treatment Responders

    To compare the percentage of treatment responders (defined as patients with MSSBP \< 140 mmHg or demonstrating a decrease from baseline of ≥ 20 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

    Time frame: 3 and 6 weeks

  4. Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks

    To compare the change from baseline in MSSBP and MSDBP after 12 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

    Time frame: Baseline to week 12

  5. Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit

    To assess the incidence of peripheral edema occurring with valsartan/amlodipine-based regimen versus losartan-based regimen in patients with Stage 2 systolic hypertension.

    Time frame: 3, 6, 9 and 12 weeks

07

Results

Posted Feb 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartan/Amlodipine/HCTZLosartan/HCTZ
Started241247
Completed207209
Not completed3438
Withdrew: Adverse event1610
Withdrew: Abnormal test procedure results20
Withdrew: Unsatisfactory therapeutic effects512
Withdrew: Patient withdrew consent49
Withdrew: Lost to follow-up65
Withdrew: Protocol deviation12

Outcome measures

PrimaryChange in Mean Sitting Systolic Blood Pressure After 6 Weeks

To compare the change from baseline in mean sitting systolic blood pressure (MSSBP) after 6 weeks of valsartan/amlodipine-based regimen with a losartan-based regimen in patients with Stage 2 systolic hypertension.

Time frame:
Baseline to Week 6
Reported as:
Mean · mmHg
Change in Mean Sitting Systolic Blood Pressure After 6 Weeks
mmHgValsartan/Amlodipine/HCTZLosartan/HCTZ
Baseline166.8 ± 7.03168.5 ± 9.03
Week 6135.5 ± 16.26142.5 ± 18.89
Change from Baseline to Week 6-31.3 ± 15.87-26.0 ± 16.62
SecondaryChange in Mean Sitting Diastolic Blood Pressure After 6 Weeks

To compare the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

Time frame:
Baseline to Week 6
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks
mmHgValsartan/Amlodipine/HCTZLosartan/HCTZ
Baseline98.6 ± 7.7197.6 ± 7.88
Week 685.1 ± 10.0588.5 ± 11.36
Change from Baseline to Week 6-13.6 ± 9.48-9.1 ± 10.03
SecondaryCumulative Percentage of Patients Achieving Blood Pressure Control

To compare the percentage of patients achieving blood pressure control (defined as patients achieving MSSBP \< 140 mmHg and MSDBP \< 90 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

Time frame:
3 and 6 weeks
Reported as:
Number · cumulative percentage of patients
Cumulative Percentage of Patients Achieving Blood Pressure Control
cumulative percentage of patientsValsartan/Amlodipine/HCTZLosartan/HCTZ
Week 330.515.3
Week 661.547.1
SecondaryCumulative Percentage of Treatment Responders

To compare the percentage of treatment responders (defined as patients with MSSBP \< 140 mmHg or demonstrating a decrease from baseline of ≥ 20 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

Time frame:
3 and 6 weeks
Reported as:
Number · Cumulative percentage of responders
Cumulative Percentage of Treatment Responders
Cumulative percentage of respondersValsartan/Amlodipine/HCTZLosartan/HCTZ
Week 365.334.3
Week 687.071.5
SecondaryChange in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks

To compare the change from baseline in MSSBP and MSDBP after 12 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.

Time frame:
Baseline to week 12
Reported as:
Mean · mmHg
Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks
mmHgValsartan/Amlodipine/HCTZLosartan/HCTZ
Baseline MSSBP166.8 ± 7.03168.5 ± 9.03
Week 12 MSSBP130.8 ± 16.22134.3 ± 19.41
Change in MSSBP from baseline to Week 12-36.0 ± 16.08-34.2 ± 17.69
Baseline MSDBP98.6 ± 7.7197.6 ± 7.88
Week 12 MSDBP82.5 ± 10.1882.5 ± 11.43
Change in MSDBP from baseline to Week 12-16.1 ± 9.91-15.1 ± 10.57
SecondaryCumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit

To assess the incidence of peripheral edema occurring with valsartan/amlodipine-based regimen versus losartan-based regimen in patients with Stage 2 systolic hypertension.

Time frame:
3, 6, 9 and 12 weeks
Reported as:
Number · cumulative percentage of patients
Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit
cumulative percentage of patientsValsartan/Amlodipine/HCTZLosartan/HCTZ
Week 30.80.8
Week 60.80.8
Week 91.30.8
Week 122.94.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan / Amlodipine / HCTZ—1/241 (0.4%)13/241 (5.4%)
Losartan / HCTZ—2/247 (0.8%)8/247 (3.2%)
Most frequent serious events
Most frequent serious events
EventValsartan / Amlodipine / HCTZLosartan / HCTZ
Non-cardiac chest painGeneral disorders1/2410/247
Urinary tract infectionInfections and infestations0/2411/247
DizzinessNervous system disorders0/2411/247
Most frequent other events
Most frequent other events
EventValsartan / Amlodipine / HCTZLosartan / HCTZ
DizzinessNervous system disorders13/2418/247

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan/Amlodipine/HCTZLosartan/HCTZTotal
Mean55.0 ± 9.8357.1 ± 9.6956.1 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/Amlodipine/HCTZLosartan/HCTZTotal
Female102111213
Male139136275
08

Study locations

1 site
  • sites in USA
    East Hanover, New Jersey, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2009
First posted
Jul 2, 2009
Start
Jul 2009
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Feb 4, 2011
Last update
Mar 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00931710
Lead sponsor
Novartis
First posted
Jul 2, 2009
Start date
Jul 2009
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Feb 4, 2011
Last update
Mar 7, 2011

Study contacts

Novartis Pharmaceuticals
study director · 862-778-8300
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine · Hydrochlorothiazide

Start the discussion